Study on the effect of Prodigiosin on adriamycin-resistant human breast cancer cells MCF-7/ADR
Objective To investigate the effect of Prodigiosin on adriamycin-resistant human breast cancer cell line MCF-7/ADR.Methods Prodigiosin was produced by plate fermentation of Serratia marcescens WA12-1-18.In vitro activity of Prodigiosin and the drug resistance index of MCF-7/ADR were determined by CCK-8.A subcutaneous xenograft tumor model was established in nude mice,and Prodigiosin with 5.0,2.5 mg/kg or equal volume saline were administered through intraperitoneal injection in high and low dose groups ɑnd normal saline control group once every 4 days for 24 days.The tumor volume,weight,and nude mouse body mass were observed.HE staining was used to observe the pathological conditions of transplanted tumor tissue and major organs in nude mice.Immunohistochemistry was used to detect the expression of Ki-67 in transplanted tumors.Results The purity of Prodigiosin was 95.18%,and the IC50 of Prodigiosin to MCF-7 and MCF-7/ADR were 0.484 μg/mL and 0.264 μg/mL,respectively.The drug resistance index of MCF-7/ADR was 13,which was in line with the requirement of drug-resistant cell strains.The growth rate of transplanted tumors in nude mice treated with Prodigiosin was slower than that in the saline group,with sparse arrangement of tumor cells,small nuclei,and lighter staining.After Ki-67 staining,the brown color significantly decreased.The tumor inhibition rates of the 2.5 mg/kg and 5 mg/kg groups of Prodigiosin in MCF-7/ADR bearing nude mice were 37.23%and 53.72%,respectively.In addition,there was no significant difference in body weight among the groups of nude mice,and there were no significant pathological changes in the main organs.Conclusion Prodigiosin can inhibit the growth of adriamycin-resistant human breast cancer cell MCF-7/ADR in nude mice without obvious toxic and side effects,which provides an experimental basis for the clinical application of Prodigiosin in adriamycin-resistant human breast cancer.
adriamycin-resistant human breast cancer MCF-7/ADRProdigiosinnude micesubcutaneous xenograft tumor
万方数据
维普
